Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: November 13, 2019)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Genetics/Family History


Managing Side Effects

No Travel Required

Predicting Response to Treatment




NEAREST SITE: 1739 miles
Washington University School of Medicine
Saint Louis,MO

VISITS: At least 1 visit every 2 months for 1 year


NCT ID: NCT03088527

RAD140 for Postmenopausal Women With HR+ Advanced Breast Cancer

A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Scientific Title

To investigate the safety, best dose, and effects (good and bad) of an investigational hormone therapy called RAD140 in patients whose tumors are no longer responding to standard treatments.
Who is this for?
Postmenopausal women with advanced (stage III) or metastatic (stage IV) breast cancer that is estrogen receptor positive and HER2 negative.    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RAD140, by mouth </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <p class="seamTextPara"> This study is investigating the safety, best dose, and effect (good or bad) of an investigational hormone therapy called RAD140 in patients whose tumors are no longer responding to standard treatments.</p>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03088527' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://investors.radiuspharm.com/releasedetail.cfm?releaseid=1042158' target='_blank'>Radius Health: RAD140</a> </li></ul>
See more